SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001213900-23-049318
Filing Date
2023-06-15
Accepted
2023-06-15 17:20:05
Documents
2
Group Members
CLS THERAPEUTICS LTD.DMITRY GENKINGEORGY TETSM. SCOT MAGUIREVICTOR TETS

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ea180429-13dcls_xeneticbio.htm SC 13D 104882
2 JOINT FILING AGREEMENT, DATED JUNE 14, 2023 ea180429ex99-1_xeneticbio.htm EX-99.1 9329
  Complete submission text file 0001213900-23-049318.txt   115984
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Subject) CIK: 0001534525 (see all company filings)

IRS No.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-89709 | Film No.: 231018503
SIC: 2834 Pharmaceutical Preparations

Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 646-617-3088
CLS Therapeutics, LLC (Filed by) CIK: 0001951493 (see all company filings)

IRS No.: 920236145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D